First, to date, only three randomized clinical trials investigating the efficacy and safety of anti-PD-1/PD-L1 antibodies for previously treated NSCLC as second-line treatment have been conducted, so the number of reports incorporated in this meta-analysis was hence limited. Here, CD274 is linked to non-small cell lung carcinoma.